Regulation of advanced therapy medicinal products in Europe and the role of academia

Cytotherapy

Volumn 16, Issue 3, 2014, Pages 289-297

  Pearce, Kim F ^a   Hildebrandt, Martin ^c   Greinix, Hildegard ^d   Scheding, Stefan ^e   Koehl, Ulrike ^f   Worel, Nina ^d   Apperley, Jane ^g   Edinger, Matthius ^h   Hauser, Andrea ^h   Mischak Weissinger, Eva ^f   Dickinson, Anne M ^a   Lowdell, Mark W ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e LUND UNIVERSITY   (Sweden)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Advanced therapy medicinal products; European Union; Good manufacturing practice; Manufacturing; Regulation

Indexed keywords

ADVANCED THERAPY MEDICINAL PRODUCTS; EUROPEAN UNION; GOOD MANUFACTURING PRACTICE; MANUFACTURING; REGULATION;

ACADEMIC MEDICAL CENTERS; ANIMALS; BIOTECHNOLOGY; CELL- AND TISSUE-BASED THERAPY; COMMERCE; EUROPEAN UNION; GENETIC THERAPY; GOVERNMENT REGULATION; GUIDELINE ADHERENCE; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84895170844     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.08.003     Document Type: Article

References (11)

1. Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004. Official Journal of the European Union. 2007;L 324:121-131.
2. Maciulaitis R., D'Apote L., Buchanan A., Pioppo L., Schneider C.K. Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. Mol Ther 2012, 20:483-512.
3. Sethe S., Batkai C., Dickinson A., Hildebrandt M. Manufacture of advanced therapies: academia meets industry. Regulatory Rapporteur 2011, 8:7-8.
4. Barnett V. Elements of Sampling Theory 1974, English Universities Press, London.
5. Abdi H., Valentin D. Multiple correspondence analysis. Encyclopaedia of Measurement and Statistics 2007, Sage, Thousand Oaks, California. N. Salkind (Ed.).
6. Bendixen M. A Practical Guide to the Use of Correspondence Analysis in Marketing Research. Marketing Bulletin, 14, Technical Note 2. 2003. http://marketing-bulletin.massey.ac.nz/V14/MB_V14_T2_Bendixen.pdf.
7. Greenacre M. Correspondence Analysis in Practice 2007, Chapman & Hall, London. 2nd ed.
8. Greenacre M. Biplots in Practice. Available free on-line. http://www.multivariatestatistics.org/publications.html.
9. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltis N. Cytokine storm in a phase I trial of the anti-CD28 monoclonal antibody TGN1412. NEngl J Med 2006, 355:1018-1028.
10. Lowdell M.W., Birchall M., Thrasher A.J. Use of one-off, compassionate use, advanced therapy medicinal products (ATMP) as a safe and valid alternative to animal models for pre-clinical data for clinical trial submissions?. Lancet 2012, 379:2341.
11. "Clinical data may, in part, compensate for non-clinical studies; inappropriate animal studies are worse than reliance upon in vitro data only." Dr Christian Schneider, Chair of EMA Committee for Advanced Therapies at ATMP Stakeholders' Workshop, EMA, London, January 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2011/11/event_detail_000545.jsp&mid=WC0b01ac058004d5c3.